Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopoly on all the good ideas," Doustdar tells Bloomberg...
Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopoly on all the good ideas," Doustdar tells Bloomberg Television. "When there is a gap, strategically or scientifically, we're looking outside to see how we can fill the gaps." (Source: Bloomberg)
Lire l’article complet sur le site source
Bloomberg — Markets (EN)